Fulvestrant

• Post Date:

  Sep 10,2017

• Expiry Date:

  Mar 09,2018

• Detailed Description:

  Cas No. :129453-61-8 Payment Method: T/T, Western Union, MoneyGram
  Basic Info.
  
  CAS:129453-61-8
  Purity:99%
  Appearance:white powder
  Synonyms: FASLODEX
  Chemical Name:(7a,17b)-7-[9-[(4,4,5,5,5-Pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol
  Molecular Fomular:C32H47F5O3S
  Molecular Weight:606.77
  Density:1.201 g/cm3
  Melting Point:104-106°C
  Boiling Point:674.8 °C at 760 mmHg
  Package:10g/foil bag
  Usage:To treat estrogen receptor positive metastatic breast cancer in postmenopausal women, with disease progression following antiestrogen therapy.
  
  
  Description:
  
  Fulvestrant also called Faslodex or AstraZeneca,is is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It works by blocking the actions of estrogen in the body. Fulvestrant is a complete estrogen receptor antagonist with no agonist effects, which in addition, accelerates the proteasomal degradation of the estrogen receptor. The drug has poor oral bioavailability, and is administered monthly via intramuscular injection.Certain types of breast cancer use estrogen to grow and multiply in the body.do not use fulvestrant if you are allergic to any ingredient in fulvestrant ,and Contact your doctor or health care provider right away if any of these apply to you.
  
  
  Applications:
  
  Many breast cancers are stimulated to grow by the female sex hormones oestrogen and progesterone. These breast cancers are called hormone sensitive or hormone receptor positive. Drugs that block the effects of these hormones can slow or stop the growth of the breast cancer cells. Fulvestrant stops oestrogen getting to the cancer cells by blocking oestrogen receptors and reducing the number of receptors the cancer cell has.
  
  Fulvestrant Acetate (Faslodex, AstraZeneca) is a drug treatment of hormone receptor-positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. It is an estrogen receptor antagonist with no agonist effects, which works by down-regulating the estrogen receptor.
  
  Fulvestrant Acetate is a selective estrogen receptor down-regulator (SERD). Fulvestrant is indicated for the treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following anti-estrogen therapy. The dosing schedule for fulvestrant remains under investigation in an attempt to optimize its effectiveness.

• CAS Registry Number:

  129453-61-8

• Synonyms:

  ;(7a,17b)-7-[9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl]estra-1,3,5(10)-triene-3,17-diol;(7alpha,17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol;(17beta)-7-{9-[(4,4,5,5,5-pentafluoropentyl)sulfinyl]nonyl}estra-1,3,5(10)-triene-3,17-diol;Faslodex;

• Molecular Formula:

  C₃₂H₄₇F₅O₃S

• Molecular Weight:

  606.7708

• Molecular Structure:

  

• Company:

  Guangzhou Kafen Biotech Co.,Ltd     [ China ]        

• Contact:

  laura Lin

• Tel:

  +8613332873040

• Fax:

• Email:

  laura@rawroid.com